MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

Returns on capital

MiNK Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

87.8%

avg 1030.1%

ROIC

-195.5%

avg 149.3%

ROA

-87.7%

avg -450.0%

Analysis

ROE is currently the strongest return metric at 87.8% versus its period average of 1030.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jennifer S. Buell

Co-Founder, President, CEO & DirectorUSD 803.69K51——

Garo H. Armen

Executive Chairman—730<0.01%

Marco Purbhoo

Head of Translational Medicine————

Terese C. Hammond

Head of Inflammatory & Pulmonary Diseases————

Melissa Orilall

Principal Financial Officer—37222<0.01%

Austin Charette

Principal Accounting Officer—3740<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 13, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

9

$119,884.19

Net Transaction Value

−$119,884.19

Net selling

Most Active

Ryan Barbara

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 12, 26

Buell Jennifer

Direct

Sell$73.3K
Jun 4, 26

Ryan Barbara

Direct

Sell$6.3K
Jun 4, 26

Ryan Barbara

Direct

Sell$12.8K
Mar 10, 26

Ryan Barbara

Direct

Sell$7.7K
Mar 10, 26

Ryan Barbara

Direct

Sell$4.6K
Mar 10, 26

Ryan Barbara

Direct

Sell$7.8K
Mar 9, 26

Ryan Barbara

Direct

Sell$2K
Mar 2, 26

Ryan Barbara

Direct

Sell$1.1K
Feb 27, 26

Ryan Barbara

Direct

Sell$4.3K

Summary

Insiders reported 0 buys worth $0.00 and 9 sells worth $119,884.19 over the last 12 months. That adds up to net selling of $119,884.19. Ryan Barbara was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does MiNK Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about INKT's management, answered from reported figures.

Who manages INKT?

MiNK Therapeutics, Inc. (INKT) lists 6 active executives. The top listed executive is Garo H. Armen, Executive Chairman.

Are INKT insiders buying or selling?

Recent insider activity shows net buying of $19.98M.